Ondine Biomedical (OBI.L) reports H1 2026 operating loss of $15.90 mln
Ondine Biomedical said its H1 2026 operating loss increased to $15.90 million. It also announced the commencement of an equity fund raising process.
90 Mln Ondine Biomedical - Announces Commencement Of Equity Fund Raising Process Source text:... com;)